What Pregabaline Teva Treats: Main Uses and Benefits

Pregabaline Teva is used to manage certain distressing symptoms across three main therapeutic areas. It is applied across domains where additional symptomatic support is needed for chronic neuropathic pain, Generalised Anxiety Disorder (GAD) in adults, and as an adjunct therapy for partial seizures in epilepsy.

The medication generally helps to ease symptoms that create noticeable physiological strain, such as the burning, stabbing pain from nerve damage or the persistent worry and tension associated with GAD. It is relevant for managing symptoms that interfere with daily comfort. Pregabaline Teva is commonly used to help with symptomatic relief, which supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

By addressing these symptom clusters, the medication contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations across these conditions.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

---

Regulatory References

1. European Medicines Agency therapeutic overview

Pregabaline Teva is authorized for use in adults (18 years and older) who do not have specific contraindications or conditions requiring restriction. The medicine's official eligibility is structured by three main regulatory classifications: Contraindicated, Conditional Use, and Use Not Recommended/Established.

Contraindicated Populations

Use of this medicine is strictly prohibited for patients who have a confirmed hypersensitivity (allergic reaction) to pregabalin or to any of the other ingredients in the formulation. This is an absolute exclusion.

Populations Requiring Conditional Use

Eligibility is conditional for certain groups, requiring special consideration by a healthcare professional:

• Renal Impairment: Patients with compromised kidney function require a mandatory adjustment (reduction) in the dose to remain eligible for safe use, as pregabalin is primarily eliminated by the kidneys.
• Elderly Patients (65 years): These patients may require a dose reduction due to the likelihood of decreased kidney function and must be monitored for increased risk of accidental injury (fall) due to effects like dizziness.
• History of Substance Abuse: Caution is required as these patients may have a higher risk for misuse, abuse, and dependence.
• Diabetic Patients: Eligibility requires monitoring for weight gain, which may necessitate changes to anti-diabetic medication.

Use Not Established/Not Recommended

• Children and Adolescents (leq 17 years): The safety and effectiveness of pregabalin have generally not been established for children under 12 and adolescents, leading to non-eligibility for routine prescribing in many indications.
• Pregnancy and Breastfeeding: Use is not recommended during pregnancy unless the potential benefit clearly outweighs the risk to the fetus, and women of child-bearing potential must use effective contraception during treatment. Use is also not recommended while breastfeeding.

Interactions with other medicines and products

The interaction profile of Pregabaline Teva is defined by the high potential for pharmacodynamic reinforcement with substances that cause Central Nervous System (CNS) depression.

Pharmacodynamic Interactions

Co-administration with other CNS depressants, including opioids, benzodiazepines, hypnotics, or muscle relaxants, results in an additive CNS depressant effect. This reinforcement increases the documented risk of somnolence, dizziness, and potentially severe respiratory depression. Similarly, Ethanol (Alcohol) enhances these effects and should not be consumed concurrently. Concomitant use with ACE inhibitors is associated with an increased risk of angioedema.

---

Pharmacokinetic and Timing Considerations

Pregabalin exhibits negligible metabolism in humans and does not inhibit or induce the major Cytochrome P450 (CYP) enzyme systems. Consequently, clinically significant pharmacokinetic interactions are not expected, and studies show no altered plasma concentrations when co-administered with common antiepileptic drugs (AEDs) like phenytoin or carbamazepine.

Administration with food decreases the rate of absorption, reducing the peak plasma concentration (Cmax) by about 25% to 30%, but the total extent of absorption (AUC) remains unaffected. Therefore, the medication can be administered with or without food.

---

Population-Specific Notes

Due to the drug’s predominant renal excretion, reduced renal function decreases drug clearance, leading to increased systemic exposure. Additionally, elderly patients (ge 65 years) may be at higher risk for CNS adverse effects when Pregabalin is used alongside other depressant medications.

The mechanism of Pregabaline Teva (Pregabalin) is defined by its highly selective action on neural communication, resulting in the modulation of overactive nerve signaling.

Modulating Presynaptic Calcium Channels

This domain covers the primary molecular target: Pregabalin binds to the alpha2delta subunit of voltage-gated calcium channels located on presynaptic neurons. This high-affinity binding modulates the channel's function and a subsequent reduction in calcium ion ( Ca^2+) influx into the nerve terminal.

Dampening Excitatory Neurotransmitter Release

The limited Ca^2+ entry acts as a molecular brake on the process of neurotransmitter release. This action specifically attenuates the release of key excitatory neurotransmitters, such as glutamate, which are central to the transmission of excitatory signals.

Stabilizing Hyperexcitable Neural Networks

By reducing excitatory chemical signals, the drug modulates neural circuits, particularly those that have become pathologically hyperexcitable. This systemic dampening results in a reduction of generalized neuronal hyperexcitability, which is the core physiological consequence produced by the drug's mechanism.

Official Administration Guidelines for Pregabalin

Pregabalin hard capsules are for oral use and must be taken exactly as prescribed by a healthcare provider. The official instructions for use emphasize a specific dosing schedule and dose adjustment rules.

Administration and Schedule

• Route: Oral (swallow the hard capsule whole).
• Timing: The medicine can be taken with or without food.
• Frequency: The total daily dose is divided and administered in two (BID) or three (TID) doses per day. Doses should be taken at roughly the same time(s) each day to maintain consistent drug levels.

Dosing and Adjustment

The total daily dose typically ranges from 150 mg to 600 mg. Treatment usually begins at a low starting dose (e.g., 150 mg per day), which may be gradually increased over one or more weeks based on the official regimen for the specific indication. The maximum daily dose is 600 mg.

Population Group	Special Dosing Instruction
Elderly Patients (>65 yrs)	May require a dose reduction due to decreased kidney function.
Renal Impairment	The dose must be individualized and reduced based on creatinine clearance, as pregabalin is eliminated primarily by the kidneys.
Haemodialysis	Patients require an adjusted daily dose plus a single supplementary dose immediately following every 4-hour haemodialysis treatment.
Children/Adolescents	Safety and efficacy have not been established; use is generally not recommended.

nMissed Dose and Discontinuation

If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule; do not take a double dose.

Treatment must not be stopped suddenly. If the medicine needs to be discontinued, the dosage should be tapered gradually over a minimum period of one week.

Recent Clinical Evidence Overview

Summary of Mechanism and Core Findings

Research has explored Pregabalin's mechanism of action, which involves binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding modulates the release of certain excitatory neurotransmitters. The clinical trials reviewed investigated the effect of this action in conditions such as neuropathic pain (including diabetic peripheral neuropathy and post-herpetic neuralgia), fibromyalgia, and as an adjunctive therapy for partial-onset seizures.

Clinical trials examined whether changes in pain scores, sleep interference scores, and patient quality of life metrics were observed in comparison to a placebo.

Study Designs and Patient Populations

Primary efficacy studies were typically randomized, double-blind, and placebo-controlled trials with durations ranging from 5 to 13 weeks. These studies generally included adult participants aged 18 and older who reported a baseline pain score above a defined threshold on an 11-point scale.

The research primarily included generally healthy adult populations specific to the disease being studied, but studies have also been conducted to evaluate its use across a range of ages, including certain pediatric populations for seizure treatment.

Long-term and Combination Data

Follow-up research has explored potential correlations between the drug's use and outcomes over longer periods, with some trials extending up to a year or more. Studies have also been conducted to assess the effects of Pregabalin when co-administered with other standard therapies. Trial authors have published hypotheses regarding how the co-administration may influence outcomes for individuals whose condition was not adequately managed by monotherapy alone. The elimination of the drug is closely linked to kidney function, and research addresses its metabolism and clearance across different levels of renal function.

Common questions about Pregabaline Teva (FAQ)

---

Q: Does Pregabaline Teva cause weight gain in most people?

A: Official regulatory documents list Weight Increased as a Common side effect, meaning it may affect up to 1 in 10 people who use the medication. Official information states that monitoring for weight gain may be necessary, particularly for diabetic patients.

Q: Can older adults use Pregabaline Teva?

A: Yes, older adults can use this medicine, but its use is conditional and requires caution. Official information indicates that patients aged 65 years and older may need a dose reduction because kidney function tends to decrease with age, and the medicine is primarily eliminated by the kidneys. Official information indicates that this population may be monitored for an increased risk of falls due to potential side effects like dizziness.

Q: Is it safe to drive or operate machinery while taking this medicine?

A: Official labeling documents carry warnings that this medicine commonly causes side effects such as dizziness, somnolence (sleepiness), and blurred vision. Regulatory information suggests caution, as these effects may impair abilities, and patients should be aware of their response before undertaking activities that require mental alertness.

Q: Does Pregabaline Teva have a risk of misuse or dependence?

A: Regulatory labeling states that the active ingredient, pregabalin, is associated with a risk of misuse, abuse, and physical dependence. The medicine is classified as a controlled substance in the United States, which reflects its potential for misuse and dependence. Patients with a history of substance abuse may require closer monitoring.

Q: Can Pregabaline Teva affect memory?

A: The official documentation on adverse effects notes that central nervous system (CNS) effects are common. Confusion is listed as a common side effect, and other related effects such as impaired attention and memory impairment are also documented in the detailed adverse event sections.

Q: What should I do if I notice unusual changes in my thinking while using Pregabaline Teva?

A: Regulatory guidance for this class of medicine includes a warning about the risk of suicidal thoughts or behavior. Official information describes that if unusual changes in mood, behavior, or thoughts are noted, the prescriber should be contacted for evaluation.

Q: Are generic versions of Pregabaline considered the same as the brand name?

A: Pregabaline Teva is a generic brand variant of the active ingredient pregabalin. Regulatory requirements for approval state that generic medicines must demonstrate bioequivalence to the original branded product. Bioequivalence means the medicine contains the same active ingredient and is designed to work in the body in the same way, achieving the same concentration levels.

Q: Does Pregabaline Teva interact with herbal supplements like St. John's Wort?

A: The medicine is noted to have minimal potential for drug-drug interactions, as it undergoes negligible metabolism in the body. However, the official product information does not explicitly address the interaction profile with specific herbal supplements like St. John's Wort. Other CNS depressant substances are noted to reinforce side effects.

Q: How long does it usually take to notice an effect from Pregabaline Teva?

A: Studies indicate that the medicine is rapidly absorbed after being taken, but the full therapeutic effect can take longer to develop. Official clinical summaries suggest that for conditions like nerve pain, patients may take one to two weeks of consistent treatment before they notice the full effect of the medicine.

Q: Can Pregabaline Teva affect your mood or cause anxiety?

A: Yes, official documents report that the medication can affect mood. Adverse effects like euphoric mood, confusion, and irritability are listed as Common side effects. Additionally, anxiety is noted as an Uncommon side effect in the official documentation.

Q: Are there different brand names for the active ingredient in Pregabaline Teva?

A: The active ingredient, pregabalin, is sold under various trade names globally. The original brand name for this compound is Lyrica, in addition to the generic variant Pregabaline Teva and others.

Q: Is it true that Pregabaline Teva is sometimes used for fibromyalgia?

A: The medicine is officially indicated and approved for the treatment of fibromyalgia in adults. In several regions, regulatory bodies have approved it for this use based on the results of clinical studies.

Q: Is Pregabaline Teva considered a controlled substance?

A: In the United States, the active ingredient pregabalin is legally classified as a Schedule V controlled substance by the Drug Enforcement Agency (DEA). This classification is based on the compound's potential for misuse and physical dependence.

Q: Can Pregabaline Teva be used by women who are planning pregnancy?

A: The use of this medicine is not recommended during pregnancy unless a healthcare provider determines the potential benefit significantly outweighs the risk to the fetus. Official guidance describes that women of child-bearing potential are advised to use effective contraception throughout treatment, which includes the planning stage.

Q: What research evidence exists for using Pregabaline Teva for anxiety?

A: Official regulatory documents and corresponding clinical trial summaries confirm the medicine's efficacy as a treatment for Generalized Anxiety Disorder (GAD) in adults. This is one of the approved indications, established through placebo-controlled studies.

Q: What is the connection between Pregabaline Teva and eye/vision changes?

A: The official adverse effects documentation notes that vision-related side effects occur. Common effects include blurred vision and diplopia (double vision). More seriously, loss of vision has been reported as an uncommon effect in post-marketing experience.

Q: Can Pregabaline Teva affect a person's energy levels?

A: The medication can affect energy levels due to its action on the central nervous system. Somnolence (sleepiness) is listed as a Very Common side effect. Other effects documented in official sources that relate to energy include fatigue and lethargy.

Q: Does Pregabaline Teva treat the cause of the pain or just the symptoms?

A: The medicine's action is described in official documents as binding to a calcium channel subunit to modulate the release of excitatory neurotransmitters. This function serves to dampen overactive nerve signaling that causes the symptoms of pain, rather than repairing or resolving the underlying physical condition that originally caused the nerve damage.

Q: Can Pregabaline Teva be taken with blood pressure medicine?

A: The official interactions profile notes that concurrent use with ACE inhibitors, which are a common class of blood pressure medicine, is associated with an increased risk of angioedema (swelling of the face, lips, or tongue). The general warnings do not detail interactions with all other specific types of blood pressure medicines.

Q: Is Pregabaline Teva commonly prescribed to treat pain after shingles?

A: The medicine is officially indicated and approved for the treatment of post-herpetic neuralgia, which is the persistent nerve pain that can occur after a shingles (herpes zoster) infection.

Q: What kinds of people are excluded from using Pregabaline Teva based on existing medical conditions?

A: The medicine is strictly contraindicated (prohibited) only for patients who have a confirmed hypersensitivity (allergic reaction) to pregabalin or any of the other ingredients in the formulation. Patients with other medical conditions, like kidney impairment or diabetes, may be eligible but require careful dose adjustment and monitoring.

Official Storage and Disposal Requirements

The storage and disposal instructions for Pregabaline Teva are based on regulatory labeling to ensure product stability and safety.

Scope Element	Official Regulatory Information
Storage Conditions	No special storage conditions are required for the product in its original packaging.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability Period	The product is stable for 3 months after the initial opening of the bottle (oral solution).
Environmental Rule	Do not throw away any medicines via wastewater or household waste.
Disposal Method	Dispose of unused or expired product through a pharmacist or official drug take-back program according to local regulations.

This medication must remain in its original container until use. The official disposal guidelines prohibit discarding the medicine into the water supply to protect the environment and advise using established pharmaceutical waste collection methods.